You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

The Role of Type 2 Inflammation in Moderate-to-Severe AD

In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.
Stephan Weidinger
MD, PhD
Stephan Weidinger

Learning objectives

  • • Explore how type 2 inflammation, including the type 2 cytokines IL-4 and IL-13, contributes to the pathophysiology of AD
  • • Discuss the role of type 2 inflammation in the risk for developing other type 2 diseases in AD
Tags
expert insightssymposium
MAT-GLB-2406718 - 3.0 - 02/2025

About this expert

Dermatology

Stephan Weidinger

MD, PhD

Professor and Chair for Dermatology at the Christian-Albrechts-University; Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, Campus Kiel, Germany

See author’s profile
Stephan Weidinger

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

AD and PN: Commonalities and Differences – A Case Study
Dermatology
expert video

AD and PN: Commonalities and Differences – A Case Study

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
Dermatology
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

Differences in Manifestations of Type 2 Inflammatory Diseases
Dermatology
expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

Mast Cells and the Neuroimmune Axis in CSU
Dermatology
expert video

Mast Cells and the Neuroimmune Axis in CSU

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions
Dermatology
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview
Dermatology
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Role of Type 2 Inflammation in Chronic Inflammatory Diseases
Dermatology
expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview
Dermatology
expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
Dermatology
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis
Dermatology
expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology
Dermatology
expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics
Dermatology
Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Exploring Neurosensitization and Pain in Prurigo Nodularis
Dermatology
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis
Dermatology
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Describing Disease Control in PN
Dermatology
expert video

Describing Disease Control in PN

What is Early Intervention in AD?
Dermatology
expert video

What is Early Intervention in AD?

Disease Modification in AD
Dermatology
expert video

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin
Dermatology
expert video

Systemic Inflammation in AD – Beyond the Skin

Dysbiosis, Skin Infections, and Itch
Dermatology
expert video

Dysbiosis, Skin Infections, and Itch

Skin Barrier Dysfunction in AD
Dermatology
expert video

Skin Barrier Dysfunction in AD

Early Intervention and the Potential for Disease Modification in Children With AD
Dermatology
expert video

Early Intervention and the Potential for Disease Modification in Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD
Dermatology
expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
Dermatology
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

The Impact of Skin Dysbiosis on Atopic Dermatitis
Dermatology
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
expert video

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in BP
Dermatology
expert video

Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies
Dermatology
expert video

Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers
Dermatology
expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

Barrier Tight Junction Disruption in Atopic Dermatitis
Dermatology
expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance 

The Burden of Atopic Dermatitis in Children – Bullying in School
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Bullying in School

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease
Dermatology
expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

The Role of Epithelial Barrier Components in AD: Insights and Implications
Dermatology
expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD
Dermatology
expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

The Potential Impact of Early Intervention in Atopic Dermatitis in Children
Dermatology
expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
Dermatology
expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

Managing Injection Pain in Children
Dermatology
expert video

Managing Injection Pain in Children

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN
Dermatology
expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region